NASDAQ:OSMT Osmotica Pharmaceuticals (OSMT) Stock Price, News & Analysis → Biden replacement revealed? (From Paradigm Press) (Ad) Free OSMT Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.98▼$1.4952-Week Range N/AVolume296,500 shsAverage Volume396,682 shsMarket Capitalization$69.47 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Osmotica Pharmaceuticals alerts: Email Address Ad Paradigm PressBiden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.See his shocking evidence in this new report About Osmotica Pharmaceuticals Stock (NASDAQ:OSMT)Osmotica Pharmaceuticals Plc engages in the development and commercialization of products for neurology and women's health. Its products include Upneeq, M-72, Arbaclofen ER, OS870, Divigel, OB Complete, Methylphenidate ER, Venlafaxine ER tablets (VERT), Hydromorphone ER, Sodium Benzoate/Sodium Phenylacetate, Oxybutynin ER, Prescription Prenatal Vitamins, Chlorzoxazone (Lorzone AG), Tramadol ER (ConZip AG), Nitrofurantoin and Osmodex ANDAs. The company was founded in 1986 and is headquartered in Bridgewater, NJ.Read More Ad Paradigm PressBiden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.See his shocking evidence in this new report OSMT Stock News HeadlinesMarch 6, 2024 | wsj.comVanda Pharmaceuticals Inc.December 19, 2023 | investing.comRVL Pharmaceuticals PLC (RVLPQ)May 2, 2024 | Stansberry Research (Ad)The Long-Awaited End of America UpdateA 995% Gain Last Time We Shared this "Election Secret" It's a straightforward way to come out on top no matter who wins this November… It's not cryptos, or options, and anyone can do it.August 14, 2023 | markets.businessinsider.comOsmotica Pharmaceuticals is about to announce its earnings — here's what to expectMarch 19, 2023 | markets.businessinsider.comWhat Wall Street expects from Osmotica Pharmaceuticals's earningsJanuary 19, 2022 | nz.finance.yahoo.comGRO Biosciences Appoints Rakhshita Dhar to its Board of DirectorsJanuary 19, 2022 | finance.yahoo.comUPDATE – Osmotica Pharmaceuticals plc Announces Corporate Name Change to RVL Pharmaceuticals plc, New Ticker Symbol “RVLP,” Plans to Launch UPNEEQ® into the Medical Aesthetics Market, and Provides Fourth Quarter 2022 Net Sales GuidanceJanuary 19, 2022 | benzinga.comOsmotica Pharmaceuticals Announces Corporate Name Change to RVL Pharmaceuticals plc With New Ticker Symbol 'RVLP'May 2, 2024 | Stansberry Research (Ad)The Long-Awaited End of America UpdateA 995% Gain Last Time We Shared this "Election Secret" It's a straightforward way to come out on top no matter who wins this November… It's not cryptos, or options, and anyone can do it.January 19, 2022 | finance.yahoo.comOsmotica Pharmaceuticals plc Announces Corporate Name Change to RVL Pharmaceuticals plc, New Ticker Symbol “RVLP,” Plans to Launch UPNEEQ® into the Medical Aesthetics Market, and Provides Fourth Quarter 2022 Net Sales GuidanceJanuary 18, 2022 | finance.yahoo.comRVL Pharmaceuticals to Host UPNEEQ® Overview and Business Update Webcast on January 19, 2022January 6, 2022 | finance.yahoo.comOsmotica Pharmaceuticals plc to Host UPNEEQ® Overview and Business Update Call on January 19, 2022December 22, 2021 | nasdaq.comJames Schaub Is The Executive VP & COO of Osmotica Pharmaceuticals plc (NASDAQ:OSMT) And They Just Picked Up 30% More SharesDecember 20, 2021 | finance.yahoo.comOsmotica Pharmaceuticals plc to Present at H.C. Wainwright Bioconnect ConferenceNovember 17, 2021 | seekingalpha.comOsmotica Pharmaceuticals plc (OSMT) CEO Brian Markison on Q3 2021 Results - Earnings Call TranscriptNovember 17, 2021 | finance.yahoo.comOsmotica Pharmaceuticals (NASDAQ:OSMT shareholders incur further losses as stock declines 13% this week, taking three-year losses to 78%November 16, 2021 | finance.yahoo.comOsmotica Pharmaceuticals (OSMT) Reports Q3 Loss, Misses Revenue EstimatesNovember 15, 2021 | finance.yahoo.comOsmotica Pharmaceuticals plc Reports Third Quarter 2021 Results and Provides Business UpdateNovember 15, 2021 | finance.yahoo.comOsmotica Pharmaceuticals plc to Present at Jefferies London Virtual Healthcare Conference 2021November 14, 2021 | markets.businessinsider.comOsmotica Pharmaceuticals earnings: here's what Wall Street expectsNovember 11, 2021 | finance.yahoo.comOsmotica Pharmaceuticals plc to Provide Third Quarter 2021 Business and Financial Update on November 15, 2021November 2, 2021 | finance.yahoo.comAnalysts Estimate Osmotica Pharmaceuticals (OSMT) to Report a Decline in Earnings: What to Look Out forOctober 13, 2021 | finance.yahoo.comOsmotica Pharmaceuticals plc Announces Closing of $35 Million Underwritten Public OfferingOctober 7, 2021 | msn.comBRIEF-Osmotica Pharmaceuticals PLC Announces Debt Financing From Athyrium Capital Management Of Up To $100 MlnOctober 7, 2021 | marketwatch.comOsmotica Pharma Shares Drop 37% After Note Purchase AgreementOctober 7, 2021 | finance.yahoo.comOsmotica Pharmaceuticals plc Announces Proposed Underwritten Public OfferingOctober 7, 2021 | finance.yahoo.comOsmotica Pharmaceuticals Announces Pricing of $35 Million Underwritten Public OfferingSee More Headlines Receive OSMT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Osmotica Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/15/2021Today5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:OSMT CUSIPN/A CIK1739426 Webwww.osmotica.com Phone(908) 809-1300FaxN/AEmployees302Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.59) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-79,590,000.00 Net Margins-138.76% Pretax Margin-167.59% Return on Equity-81.23% Return on Assets-20.97% Debt Debt-to-Equity RatioN/A Current Ratio0.43 Quick Ratio0.42 Sales & Book Value Annual Sales$177.88 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow1.00 Book Value$1.50 per share Price / BookN/AMiscellaneous Outstanding Shares62,585,000Free Float59,318,000Market Cap$69.47 million OptionableNot Optionable Beta2.34 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesBrian A. MarkisonChairman & Chief Executive OfficerJames SchaubChief Operating Officer & Executive Vice PresidentAndrew J. EinhornChief Financial OfficerTina DevriesExecutive VP-Research & DevelopmentSergio AlegreVice President-Global ComplianceKey CompetitorsLandos BiopharmaNASDAQ:LABPSELLAS Life Sciences GroupNASDAQ:SLSAssembly BiosciencesNASDAQ:ASMBCarisma TherapeuticsNASDAQ:CARMYS BiopharmaNASDAQ:YSView All Competitors OSMT Stock Analysis - Frequently Asked Questions How were Osmotica Pharmaceuticals' earnings last quarter? Osmotica Pharmaceuticals plc (NASDAQ:OSMT) posted its earnings results on Monday, November, 15th. The company reported ($0.42) earnings per share for the quarter, missing analysts' consensus estimates of ($0.36) by $0.06. The business earned $2.20 million during the quarter, compared to analysts' expectations of $2.39 million. Osmotica Pharmaceuticals had a negative net margin of 138.76% and a negative trailing twelve-month return on equity of 81.23%. During the same period last year, the business posted ($0.14) earnings per share. What other stocks do shareholders of Osmotica Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Osmotica Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Pfizer (PFE), AbbVie (ABBV), AT&T (T), Idera Pharmaceuticals (IDRA), OPKO Health (OPK), SCYNEXIS (SCYX), Zynerba Pharmaceuticals (ZYNE) and When did Osmotica Pharmaceuticals IPO? Osmotica Pharmaceuticals (OSMT) raised $58 million in an IPO on Thursday, October 18th 2018. The company issued 8,300,000 shares at $7.00 per share. Jefferies, Barclays, RBC Capital MarketsWells and Fargo Securities acted as the underwriters for the IPO. This page (NASDAQ:OSMT) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldAI finds its first serious applicationWall Street StarHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportDollar CancelledLear CapitalRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold GroupDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressA.I. is a Tidal Wave - Here’s What to BuyChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Osmotica Pharmaceuticals plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
